Retinal Nerve Fiber Layer Damage as Assessed by Optical Coherence Tomography in Eyes with a Visual Field Defect Detected
by Frequency Doubling Technology Perimetry but Not by Standard Automated Perimetry
Purpose
To determine whether the visual field (VF) loss detected by frequency doubling technology perimetry (FDT) but not by standard automated perimetry (SAP) is associated with retinal nerve fiber layer (RNFL) damage measured using optical coherence tomography (OCT).
Design
Observational case–control study.
Participants
Ninety-three subjects were recruited from the longitudinal University of California, San Diego, Diagnostic Innovations in Glaucoma Study.
Methods
All participants had ≥2 reliable SAP–Swedish Interactive Testing Algorithm and FDT 24-2 tests and at least one Stratus OCT test, all conducted within a 6-month time window.
Main Outcome Measures
Retinal nerve fiber layer thickness measured with OCT and the number of sectors with OCT-measured RNFL thickness lower than the 95% confidence interval (CI) or 99% CI based on the instrument’s normative database.
Results
Compared with those with normal SAP and FDT results, a significantly higher proportion of subjects with normal SAP and abnormal FDT results had OCT-measured RNFL thickness outside 95% limits in the inferior and superior quadrants (P = 0.048) and outside 99% limits in the inferior quadrant (P = 0.010).
Conclusions
When SAP is within normal range, some patients with VF loss detected by FDT show a decreased RNFL thickness, possibly indicating the presence of glaucomatous damage. These results support the validity of FDT as a tool to detect early glaucoma.
To access this article, please choose from the options below
Manuscript no. 2006-348.
Disclosure: research support from Carl Zeiss Meditec (LMZ, PAS, RNW), Heidelberg Engineering (LMZ, RNW), Welch-Allyn (PAS), and Haag-Streit (PAS). Honoraria from Heidelberg Engineering (LMZ, RNW) and Carl Zeiss Meditec (RNW).
Supported by the National Institutes of Health, Bethesda, Maryland (grant nos. EY11008 [LMZ], EY08208 [PAS]). Participant retention incentive grants in the form of glaucoma medication at no cost: Alcon Laboratories, Inc., Fort Worth, Texas; Allergan, Irvine, California; Pfizer, Inc., New York, New York; and Santen, Inc., Napa, California.
PII: S0161-6420(06)01313-3
doi:10.1016/j.ophtha.2006.09.015
© 2007 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

